Table 1 Demographics of 1,165 oncology patients aged 15–39 years by treatment modality

Sex, n (%)

0.33

 Male

443

(50)

88

(44)

35

(47)

 Female

448

(50)

112

(56)

39

(53)

Race, n (%)

0.16

 White

716

(80)

163

(82)

64

(86)

 Black

142

(16)

25

(13)

7

(9)

 Other

33

(4)

11

(6)

3

(4)

 Unknown

0

(0)

1

(0)

0

(0)

Age at first treatment (y; median, IQR)

29

(23–35)

 < 0.001

 15–19, n (%)

115

(13)

12

(6)

10

(13)

 20–24, n (%)

174

(20)

19

(10)

10

(14)

 25–29, n (%)

184

(21)

34

(17)

13

(18)

 30–34, n (%)

188

(21)

61

(31)

20

(27)

 35–39, n (%)

230

(26)

74

(37)

21

(28)

Treatment duration, mo. (median, IQR)

 Anthracycline

2

(0.0 – 5.0)

-

2

(0.0 – 7.0)

0.34

 VEGF inhibitor

-

3

(0.0 – 9.0)

2

(0.0 – 5.0)

0.04

Primary cancer diagnosis, n (%)

 < 0.001

 Brain and spinal

12

(1)

51

(26)

2

(3)

 Leukemia

303

(34)

1

(1)

19

(26)

 Lymphoma

305

(34)

2

(0)

0

(0)

 Sarcoma

122

(14)

31

(16)

26

(35)

 Epithelial/melanoma

134

(15)

104

(52)

10

(14)

 Other solid/unspecified tumors^a

15

(2)

11

(6)

17

(23)

Comorbidities prior to treatment, n (%)

 Hypertension

71

(8)

28

(14)

4

(5)

0.01

 Diabetes

22

(2)

10

(5)

4

(5)

0.09

 Dyslipidemia

36

(4)

11

(6)

4

(5)

0.60

 Tobacco smoking use, n (%)

0.17

  Current

57

(6)

12

(6)

5

(7)

  Former

69

(8)

34

(17)

10

(14)

  Never

765

(86)

154

(77)

59

(80)

 Cardiovascular, n (%)

  Peripheral arterial disease

5

(1)

1

(1)

1

(1)

0.69

  Coronary disease

1

(0)

0

(0)

0

(0)

*

  Cardiomyopathy/heart failure

10

(1)

1

(0)

0

(0)

*

  Cerebrovascular disease

1

(0)

0

(0)

2

(3)

*

  Charlson comorbidity index (median, IQR)

0

(0 – 1)

1

(0 – 1)

0

(0 – 1)

 < 0.001

Vital status, n (%)

 < 0.001

 Alive at last follow-up

613

(69)

87

(43)

16

(22)

 Deceased

278

(31)

113

(57)

58

(78)